The influence of PPARγ mediated MAPK and NF-κB activation in AGEs stimulated apoptosis and autophagy in human chondrocytes

Le résumé fourni par la source

Background: Advanced Glycation End Products (AGEs), which accumulate in metabolic syndrome patients and the elderly, are implicated in osteoarthritis (OA) pathogenesis. Peroxisome proliferator-activated receptor-γ (PPARγ), a nuclear receptor, has emerged as a potential therapeutic target for OA. This study investigates the molecular mechanisms by which PPARγ regulates AGEs-induced apoptosis and autophagy in human chondrocytes. Methods: Primary human chondrocytes were exposed to AGEs, either with or without the PPARγ agonist pioglitazone, as well as specific inhibitors targeting MAPK and NF-κB pathways. Autophagy levels were assessed via Western blot analysis of LC3-II, transmission electron microscopy (TEM), and GFP-LC3 imaging. Apoptosis was evaluated by measuring cleaved caspase-3, cleaved PARP, and FITC Annexin V using Western blot and flow cytometry. PPARγ expression was quantified via real-time PCR, while MAPK and NF-κB pathway activation was examined by analyzing phosphorylated ERK, JNK, p38, and IκBα levels. Additionally, MMP-13 and TNF-α expression was measured using ELISA. Results: High-dose AGEs treatment in human chondrocytes led to increased apoptosis, reduced autophagy, downregulation of PPARγ, and activation of MAPK and NF-κB pathways. Pioglitazone treatment elevated autophagy marker LC3-II while suppressing phosphorylation of MAPK components ERK and p38. Notably, inhibitors of JNK and p38 partially reversed AGEs-induced PPARγ suppression and restored autophagy. AGEs also activated the NF-κB pathway, an effect counteracted by pioglitazone. Furthermore, NF-κB inhibition enhanced autophagy in AGEs-treated chondrocytes. Compared to AGEs alone, pioglitazone, specific MAPK inhibitors (SP600125 and SB203580, but not PD98059), and NF-κB inhibitors reduced MMP-13 and TNF-α expression. Conclusions: PPARγ activation via pioglitazone mitigates AGEs-driven chondrocyte apoptosis and reinstates autophagy by regulating MAPK and NF-κB signaling. These results suggest that PPARγ agonism could serve as a dual-target therapeutic approach for OA, with pioglitazone emerging as a potential disease-modifying agent. Further clinical research is needed to confirm its therapeutic benefits in OA management.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.